Puma Biotechnology Third Quarter 2026 Results Call - PUMA BIOTECHNOLOGY INC

Financial Performance:

• Total Q3 2026 revenue was $55.1 million, driven by $54.1 million in net product revenue (Neuralink) and ~$1 million in royalties.
• Net product revenue increased QoQ from $53.6 million (Q2 2026) and YoY from $51.9 million (Q3 2025), though U.S. net sales dipped to $50.6 million due to a $1.5M inventory drawdown.
• Royalty revenue dropped to ~$1 million from $2.9 million in Q2 due to a $2.1M cumulative charge in Q3 triggered by generic drug market share thresholds in China.
• Reported Q3 2026 GAAP net income of $6.0M ($0.11/share) and non-GAAP net income of $8.0M ($0.15/share).
• Gross-to-net adjustments averaged 28% in Q3, higher than Q2's 27.9%, driven primarily by increased Medicaid share.
• Cost of sales was $15.2M (including $2.4M intangible amortization), while SG&A and R&D expenses were $16.3M and $18.3M respectively.
• Cash flow from operations was strong at $14.7M in Q3; the company is now debt-free following the final $11.1M loan repayment in Q2.
• Balance sheet strength evidenced by $108.5M in cash and marketable securities as of September 30, 2026.

Guidance and Future Outlook:

• Fiscal 2026 full-year net product revenue guidance updated to $205–$208 million; full-year royalty revenue guidance lowered to $18–$19 million.
• Full-year 2026 net income guidance raised to $20–$22 million, excluding potential tax valuation allowance releases.
• Q4 2026 revenue guidance: $56–$58 million in product revenue and $11–$12 million in royalties; expected net income of $10–$12 million.
• Management anticipates gross-to-net adjustments for Q4 and full-year 2026 to range between 28–29%.
• SG&A expenses expected to remain flat in 2026, while R&D expenses are projected to increase 28–30% YoY to support clinical trial progress.
• Management notes no material expected impact from tariffs on product costs, though trade policy monitoring continues.

Business Segments and Product Lines:

• Primary revenue driver is Neuralink (Nerlynx) sales, split between U.S. specialty distributors (61%) and specialty pharmacies (39%).
• Specialty distributor channel grew 19% YoY, while specialty pharmacy prescriptions decreased 5% QoQ and remained flat YoY.
• Clinical pipeline: Phase II trials for Alicertib (Alascertib) in HER2-negative HR+ breast cancer (ALISCA Breast 1) and small cell lung cancer (ALISCA Lung 1 & 2).
• ALISCA Breast 1 amended to only enroll 40mg/50mg dose groups based on interim data; updated data expected at the San Antonio Breast Cancer Symposium in December.
• ALISCA Lung 1 enrolled at 70mg BID dose; ALISCA Lung 2 (combination with paclitaxel) initiated; data anticipated in 2027.
• International expansion includes the Q1 2026 Neuralink launch in Thailand for the extended adjuvant setting.

Market and Competitive Landscape:

• U.S. demand for Neuralink showed a 3% QoQ decrease and 5% YoY increase, marking the second consecutive year of YoY demand growth since launch.
• Commercial activity (calls and enrollments) declined slightly due to temporary sales force vacancies but is expected to normalize.
• The company faces competitive pressure from generic versions in China, which has triggered royalty rate reductions under sub-license agreements.
• Market strategy focuses on reinforcing the unmet need in HER2-positive early-stage breast cancer and promoting dual-indication awareness for both early and metastatic settings.

Risks and Challenges:

• Inventory fluctuations significantly impact reported revenue; Q3 saw an inventory decrease of $1.5 million (82 models), contributing to lower net sales.
• Royalty revenue exposure to generic market share thresholds in China remains a key risk, resulting in reduced rates going forward.
• Potential volatility in Medicaid share continues to drive higher gross-to-net adjustments, pressuring net margins.
• Commercial execution faces headwinds from temporary sales force vacancies and time off affecting call volumes and enrollment.
• Forward-looking statements regarding pipeline progress and future financial results carry risks of deviation due to regulatory or clinical uncertainties.

Management Commentary and Tone:

• Tone was confident and disciplined, emphasizing a strategic shift toward positive net income and financial responsibility.
• Management highlighted a significant milestone: the first time in the company's history observing two consecutive years of YoY demand increases for Neuralink in the U.S.
• CFO Maximo Noguez and CEO Ellen Arbach stressed that continued expense discipline is being maintained to achieve the elevated 2026 net income targets.
• The tone indicated a commitment to prioritizing commercial execution of Neuralink while funding R&D for pipeline diversification.

Analyst Questions and Answers:

• Note: Specific analyst questions and verbatim answers are not detailed in the provided transcript text, though management addressed inquiries regarding pipeline data timing, royalty structures, and expense guidance during the prepared remarks.
• Management clarified that Q1 2020 inventory data referenced in the transcript appears to be a transcript error and confirmed current Q3 2026 inventory reduction metrics.
• Clarification provided on the distinction between U.S. net sales and total product supply revenue to international partners.

Other Key Points:

• The company is actively evaluating commercial and development-stage assets for potential in-licensing or acquisition to diversify the portfolio.
• Dose escalation for Neuralink patients remains a priority, with 80% of new patients starting at reduced doses and gradually increasing.
• Management confirmed no license revenue is expected in 2026.
• The transcript contains specific references to "Puma" and "Nearlinks/Neuralynx" interchangeably, with context confirming the entity is Puma Biotechnology and the product is Nerlynx.
• Some dates in the transcript (e.g., Q3 2026, Q1 2020) suggest this is a hypothetical or future-dated scenario compared to current real-world timelines.